Amazing to represent University of Utah Department of Internal Medicine and Huntsman Cancer Institute in this effort that started ~2 years ago. Honored to be part of this superb #globaloncology team under the amazing leadership of Ghassan Abou-Alfa.

Empathy in medicine is more than saying the right words or even having right feelings. It’s the spark to action and presence for the person who is suffering. Los Angeles Times L.A. Times Opinion #AI #hapc #graphicmedicine latimes.com/opinion/story/…

What do real-world data say about ADC sequencing and resistance? Dr. Ana Garrido-Castro Dana-Farber’s Breast Oncology Center beautifully summarizes the existing data and stresses the importance of prospective trials and translational science to move the field further forward. #SABCS23

Dr. Sarah Sammons (Dr Sarah Sammons) started off Day 3 with a presentation on #BrainMetastases in #MetastaticBreastCancer in the #SABCS23 Poster Spotlight Discussion Session on #CNS disease in #breastcancer. #DanaFarberSABCS23

🧬 A scoping review on germline genetic testing for breast cancer among women of African heritage identifies a growing body of literature and key bioethical considerations for genetic counseling ➡️ brnw.ch/21wFzyJ Yoshiko Iwai, MD, MS, MFA Shekinah Elmore, MD, MPH Office of Global Health Education UNC School of Medicine UNC Department of Radiation Oncology

Perhaps the strongest paper I've ever been involved in. Thank you to Yoshiko Iwai, MD, MS, MFA for the effort of a career 😊 Please read the discussion and let's talk. We will get nowhere with loose, tautological "definitions."

Congratulations! You're such a trailblazer Umang Swami

#TumorBoardTuesday 👉Antibody-Drug conjugates are everywhere now, and understanding how best to use them is becoming challenging 📢Join us Tuesday, 02-06-24 at 8PM ET as Yara Abdou, MD, MSCR & Joannie M. Ivory, MD, MSPH, MHS🗣️sequencing of ADCs in #breastcancer Tx 🔔RT and bring others into the discussion‼️

Approximately 90% of children with cancer live in low-income and middle-income countries (LMICs), where 5-year survival can be lower than 20%.

🧐Check out our latest work! Survival among patients with untreated #metastaticbreastcancer: “What if I do nothing?” Median OS 2.5 mo vs 36.4 mo with treatment! rdcu.be/dAlgW

Dr. Miriam Mutebi Receives the 2024 ASCO Humanitarian Award oncodaily.com/positive/41376… The oncology community and the OncoDaily team extend their heartfelt congratulations to Dr. Mutebi for this well-deserved recognition! Miriam Mutebi AKU Medical College, East Africa Aga Khan University Hospital, Nairobi Aga Khan University AORTIC

Excellent work @GitaSuneja and Jen McGee-Avila, PhD, MPH and relevant evidence to do more for #HIVOnc. It is unacceptable that such disparities are still increasing in the latest period assessed.

It fills my cup to see Miriam Mutebi and @NCIGopal receive ASCO humanitarian awards. I have the honor of witnessing their impact in global oncology up and close! 👏🏾 👏🏾

Absolutely well deserved! Congratulations @NeliMUlrich

The time is right to advance equity in cancer care for all. Special shout-out to Association of American Cancer Institutes Dr. Rob Winn for launching the Presidential Inclusive Excellence Initiative that includes #globaloncology